Rapid Tests for Assesment of TIA/Ischemic Stroke, Concussions & Risk of Posttraumatic Epilepsy

About us


DRD (Diagnostic Reagents & Devices, DRD Ltd.)is research company, based in Republic Buryatia, Russia.



DRD Biotech develops and implements in vitro diagnostic devices - rapid tests based on innovative biotech and IT-technologies.




Rapid tests for assesment of:

  • Ischemic Stroke / TIA

  • Concussions and mild TBI

  • Posttraumatic Epilepsy 

ELISA test kits for assesment of:

  • Risk of  ischemic Stroke

  • Posttraumatic epilepsy

  • Severity of brain damage after mild TBI

Our team


Our team has broad experience of the IVD market. DRD partners possess expertise in product development, regulatory and clinical affairs.


Company's consultants are recognized experts in the field of neurology, neurosurgery, development of biomarkers for brain damage, biotechnology, and clinical trials.


Open Innovations 2017

On October 16-18, Skolkovo Technopark hosted the third technology forum Open Innovation 2017. The forum is supported by the Skolkovo Foundation, the Government of the Russian Federation, and the RVC. The list of participants and speakers this year was really impressive: Nassim Teleb, Timur Bekmambetov, Ivan Bortnik, Viktor Vekselberg ...
Thanks to the Skolkovo Foundation we were able to present our tests on the forum: for 3 days DRD team answered visitors' questions, communicated with colleagues, asked experts opinions.
In addition, CEO of DRD visited the plenary session with Dmitry Medvedev, dedicated to the digital economy, where Jack Ma and Mitio Kaku shared their insights about future of the world.

Bio International Convention 2017

The beginning of the year 2017 for the DRD team was rich in performances and presentations, and one of the main events was a trip to BIO 2017!
Bio International Convention 2017 is the largest congress and exhibition event and one of the most prestigious events in the world in the field of bioindustry. In 2017, the event is held for the 24th time. Bio International Convention is the best platform for meetings and negotiations of biotechnological start-ups with leading leaders of the pharmaceutical industry, investors and potential partners.
DRD was able to get to such a significant event as part of the Skolkovo business mission, and to submit rapid tests to international experts. Within the framework of the event, DRD representatives held more than a dozen meetings and negotiations with potential partners and investors.

DRD Biotech presents rapid test for concussion!

The St. Petersburg International Economic Forum has been gathering under its roof technology companies from Russia and abroad for several years. This year we were lucky to take part in the forum: present our developments to industry experts and hold business meetings.
At the SPIEF DRD Biotech brought a new test for a concussion. The principle of the test is based on the detection in the blood of a special protein - AMPA-peptide, specific for light craniocerebral trauma or concussion.
On the sidelines of the forum there was a meeting and presentation of the test to Alexei Tsydenov, the head of the Republic of Buryatia. Alexei Tsydenov highly appreciated the potential of express tests, and expressed his interest in scaling the production of tests in  Buryatia.

The winner in the category "Innovative approaches to the prevention of chronic non-communicable diseases and the formation of culture of health" Open Innovation Marketplace competition was the company DRD Biotech (DRD Ltd.), with “Rapid test to determine brain damage». The competition was held under the  authority of the Moscow Agency of Innovation.

Moscow Department of Health has become a partner  of category and now  company will be free to be piloted in one of the Department's agencies.

Cooperation is scheduled immediately after DRD Biotech registration certificate for rapid tests.

10.26.2016 on "Open Innovation 2016" CEO of  DRD Biotech Anzhey Zhimbiev and Deputy Head of Moscow Department of Health Julia O. Antipova signed a cooperation agreement.

The prototype test for chronic cerebral ischemia.

14 October 2016 DRD Biotech presented the prototype of the "NR2-Antibody Rapid Test». The team presented a prototype to Skolkovo biomedical cluster management: everyone could test themselves on the risk of stroke.

The prototype is a test cassette, which operates from a single drop of blood from a finger. Also included: lancet, alcohol wipes, instructions and pipette for taking a blood sample. The reaction time is not more than 10 minutes.

In the near future DRD Biotech plans to create prototypes tests for ischemic stroke and a brain concussion and proceed to clinical trials in Russia.

1 / 5

Please reload

A concussion is a traumatic brain injury that alters the way how brain functions. The effect of a concussion is usually temporary and can be manifested in headaches, problems with concentration, memory, balance and coordination.


Concussions are common particularly in contact sport. Every concussion injures the brain to some extent and requests a time for brain to be healed properly. Most concussive injuries are mild, and people usually recover completely.

Mild traumatic brain injuries are most common among young people and persons of active age. Therefore medical and social costs to society can be significant. Depending on the severity of the injuries, persons may require medical attention and in some cases specialized care.


Currently, more than 2.0 million Russians are on long-term disability due to injury that amounts about 495 billion rubles, or 2.6% of GDP in annual economic loss to Russian healthcare system.



пр. 50-лет Октября, 13, Улан-Удэ, Россия, 670034


ул. Большой Бульвар, 42 стр. 1, офис 357, Москва, Россия, 143026




160 Клэйрмонт Авенью, сьют 200, Декейтер, Джорджия, США, 30030.


pr. 50 let Oktyabrya, 13, Ulan-Ude, Russia, 670034


Bolshoy bulvar, 42 b. 1, office 357, Moscow, Russia, 143026



160 Clairemont Ave, Suite 200, Decatur, GA, 30030, USA

  • Wix Facebook page
  • Twitter Classic
  • Vkontakte App Icon


Исследования осуществляются ООО "ДРД" при грантовой поддержке Фонда "Сколково"

© 2014 DRD Diagnostic Reagents Devices